San Diego-based "ARS Pharmaceuticals, which is developing an epinephrine nasal spray designed to better treat severe allergic reaction, said today that it has raised $55M in a Series D funding. The funding was led by SR One, and also included RA Capital Management, an un-named US healthcare-focused fund, and Deerfield Management. The company said it will use the funding to advance its product through approval, to support initial launch activities, and to evaluate it in clinical studies for additional indications. The company's nasal spray is an alternative to the Epipen and other epinephrine injectors, which use a needle to inject epinephrine into a patient in an emergency. ARS Pharmacetucals says its product, "Neffy", could provide an easy-to-use, convenient, and more reliable treatment for severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.